Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660.
This is a major milestone in Rebiotix’s efforts to bring the first microbiota-based therapeutic to the market to treat people that have recurrent Clostridioides difficile infection (rCDI). rCDI is a major unmet clinical need where standard of care antibiotics do not work effectively.